These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 12583549

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Antibiotic exposure and its relationship to postantibiotic effect and bactericidal activity: constant versus exponentially decreasing tobramycin concentrations against Pseudomonas aeruginosa.
    Li RC, Zhu ZY, Lee SW, Raymond K, Ling JM, Cheng AF.
    Antimicrob Agents Chemother; 1997 Aug; 41(8):1808-11. PubMed ID: 9257767
    [Abstract] [Full Text] [Related]

  • 5. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model.
    Tessier PR, Nicolau DP, Onyeji CO, Nightingale CH.
    Chemotherapy; 1999 Aug; 45(4):284-95. PubMed ID: 10394012
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
    Burkhardt O, Lehmann C, Madabushi R, Kumar V, Derendorf H, Welte T.
    J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Effect of tobramycin on characteristics of strains of Acinetobacter species].
    Hostacká A.
    Ceska Slov Farm; 2003 Jul; 52(4):193-7. PubMed ID: 12924072
    [Abstract] [Full Text] [Related]

  • 15. Urinary concentrations and antimicrobial activity of tobramycin in healthy volunteers receiving a single oral dose of a novel formulation for improved absorption.
    Loose M, Naber KG, Shields P, Reinhart H, Wagenlehner FME.
    Int J Antimicrob Agents; 2018 Mar; 51(3):422-426. PubMed ID: 29158143
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [In vitro bactericidal activity of tobramycin and amikacin alone or in combination against Pseudomonas aeruginosa isolated from patients with cystic fibrosis].
    Bertrou A, Marty N, Henry S, Agueda L, Chabanon G.
    Pathol Biol (Paris); 1990 May; 38(5):366-75. PubMed ID: 2114606
    [Abstract] [Full Text] [Related]

  • 18. Pharmacodynamics of beta-lactam antibiotics. Studies on the paradoxical and postantibiotic effects in vitro and in an animal model.
    Odenholt-Tornqvist I.
    Scand J Infect Dis Suppl; 1989 May; 58():1-55. PubMed ID: 2499924
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Changes in MIC alter responses of Pseudomonas aeruginosa to tobramycin exposure.
    Ioannides-Demos LL, Liolios L, Wood P, Spicer WJ, McLean AJ.
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1365-9. PubMed ID: 9624477
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.